^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AiRuiLi (adebrelimab)
i
Other names: SHR1316, SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
PD-L1 inhibitor
Related drugs:
16d
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer (clinicaltrials.gov)
P3, N=1000, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P3 trial
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
17d
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (clinicaltrials.gov)
P1/2, N=210, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=96 --> 210 | Trial completion date: Mar 2028 --> Mar 2029 | Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2026 --> Mar 2027
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
|
Erbitux (cetuximab) • cisplatin • carboplatin • SHR-A2102 • AiRuiLi (adebrelimab)
17d
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=24, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting | N=48 --> 24 | Trial primary completion date: Sep 2025 --> Sep 2027
Enrollment closed • Enrollment change • Trial primary completion date
|
carboplatin • etoposide IV • AiRuiLi (adebrelimab)
21d
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer (clinicaltrials.gov)
P2, N=70, Recruiting, Peking Union Medical College Hospital
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
Herceptin (trastuzumab) • Lenvima (lenvatinib) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
22d
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies (clinicaltrials.gov)
P2, N=30, Recruiting, The First Affiliated Hospital with Nanjing Medical University
New P2 trial
|
gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
1m
ACADEMY: A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC (clinicaltrials.gov)
P2, N=38, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
Trial completion date • Trial primary completion date
|
AiTan (rivoceranib) • AiRuiLi (adebrelimab)
1m
ABC-R: Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM. (clinicaltrials.gov)
P2, N=58, Recruiting, Fudan University
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • HER-2 negative + HR negative
|
Avastin (bevacizumab) • cisplatin • carboplatin • AiRuiLi (adebrelimab)
1m
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis (clinicaltrials.gov)
P2, N=102, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
capecitabine • cyclophosphamide • AiRuiLi (adebrelimab) • Navelbine oral (vinorelbine tartrate oral)
1m
NEOCRTEC2501: Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=42, Recruiting, Sun Yat-sen University
New P2 trial
|
carboplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
1m
Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer (clinicaltrials.gov)
P2, N=170, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
albumin-bound paclitaxel • cyclophosphamide • epirubicin • AiRuiLi (adebrelimab)
1m
SYSKY-2023-1262-02: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
Trial completion date • Trial primary completion date
|
AiTan (rivoceranib) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
1m
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial (clinicaltrials.gov)
P2, N=84, Not yet recruiting, Sun Yat-sen University
New P2 trial • pMMR
|
5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • AiRuiLi (adebrelimab)
Share via
